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Abstract  
 
Introduction: Photochemical internalisation (PCI), a novel minimally invasive treatment, has 
shown promising preclinical results in enhancing and site-directing the effect of anti-cancer 
drugs by illumination. The PCI treatment involves the systemic administration of a 
photosensitiser followed by a chemotherapeutic agent. Illumination is then carried out with 
a laser of a specific wavelength, to initiate localized chemotherapy release. We report the 
use of a new photosensitiser TPCS2a (Amphinex®)-mediated photochemical internalisation 
(PCI) in a phase I dose-escalation trial involving patients with advanced and recurrent 
malignancies. The aim of the study was to assess the safety and tolerability of TPCS2a –
mediated PCI with bleomycin and document preliminary anti-tumour activity. 
 
Materials and methods: Patients were administered TPCS2a on Day 0 by slow intravenous 
injection, followed by a fixed dose of 15,000 IU/m2 bleomycin, given as an infusion on Day 4. 
After 3 hours, the surface of the target tumour was illuminated with 652nm laser light (fixed 
at 60 J/cm2).  The TPCS2a starting dose was 0.25 mg/kg and then was escalated in successive 
dose cohorts of 3 patients. Adverse events were graded using Common Terminology Criteria 
for Adverse Events (CTCAE) v3 and in addition TPCS2a pharmacokinetics (PK), pain scores and 
skin photosensitivity testing were performed.  Tumour response in target lesions was 
reported using RECIST 1.1 criteria.  
 
Results: Twenty-two patients were recruited into the study and twelve patients completed 
the 3 months follow-up period. The administration of TPCS2a was found to be safe and 
tolerable by all patients. PCI-related adverse events were either local, due to the local 
inflammatory process, or systemic, mostly due to the skin photosensitising effect of TPCS2a.  
Higher transient pain response localised to the treatment site was observed. No PCI-related 
deaths were recorded in the study. 
 
Dose-limiting toxicities (DLTs) were observed in two patients at a TPCS2a dose of 1.5 mg/kg 
(skin photosensitivity and wound infection); thus the MTD (maximum tolerated dose) of 
TPCS2a was determined to be 1.0 mg/kg. TPCS2a was noted to have a rapid initial elimination 
followed by a slow elimination rate (half-life 15-22 days) and was still detectable in blood 90 
days after administration. There were no reported photosensitivity reactions reported at 
500 lux exposure (bright indoor light); whilst at 100,000 lux (direct sun light) photosensitivity 
was detected in at least one patient in all dose cohorts except at 0.125 mg/kg.  
 
Dramatic tumour responses were seen, even within this heavily pre-treated patient 
population with advanced and recurrent malignancies. At Day 28, complete response (CR) 
was observed in 11 patients (58%), partial response in 2 (10%), stable disease in 2 (10%) and 
progressive disease in only one patient (5%). All the 0.25 mg/kg cohort patients showed 
complete response. 
 
Conclusion: The TPCS2a -mediated PCI with bleomycin is safe and tolerable by all patients. 
Significant anti-tumour effects were seen with all the doses tested on several different types 
of tumours, warranting further clinical studies with the PCI technology. Based on our data, 
we have identified TPCS2a with the dose of 0.25 mg/kg as the recommended treatment dose 
for all future trials. 
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Introduction  
Photochemical internalization (PCI) is a novel technology that facilitates the delivery of 
therapeutic molecules into the cytosol of cells. It was developed to enhance targeted 
intracellular delivery of therapeutics that are not able to penetrate cellular membranes, 
including proteins, nucleic acids, and various nanoparticles, as well as some small molecule 
chemical entities. These molecules are taken up into cells by endocytosis and accumulate in 
endosomes and lysosomes where they are trapped or degraded, hence, unable to exert 
their therapeutic potential (1). PCI aims to overcome this hurdle by utilizing highly 
amphiphilic photosensitisers that are trapped in the same endocytic vesicles as the 
therapeutics. Upon exposure to light of appropriate wavelength, reactive oxygen species are 
induced, rupturing the endosomes and lysosomes and thereby releasing the contents into 
the cytosol, allowing the therapeutics to reach their targets. By site-directed illumination, 
PCI can be used to target drugs preferentially to tumour sites, reducing side effects in 
distant normal tissues. The PCI mechanism and practical application was initially described 
in preclinical models by Berg et al. in 1999, highlighting potential clinical usefulness in 
delivering cancer therapy, gene therapy and vaccination (2).   
 
Results from the in vitro evaluation showed that PCI can enhance cellular uptake of 
chemotherapeutic agents, with difficulty diffusing through the cellular membranes, resulting 
in a reverse of the multidrug resistance (MDR) process (3). In vivo animal PCI studies have 
looked at various therapeutic parameters and their outcomes. This includes tumour 
response, tumour selectivity and immunological response. PCI demonstrated a synergistic 
effect when combined with radiotherapy or after surgery. In vivo studies using PCI on animal 
models resulted in good treatment outcomes. AlPcS2a based gelonin PCI was found to cause 
significant retardation in tumour growth compared to samples treated with PDT alone (4). 
 
Both in vitro and in vivo models have shown PCI to enhance the effect of many types of 
macromolecules (1,-10) and also of some small molecule anti-cancer drugs (11-13). The 
photosensitisers used in PCI have no serious toxic effects in the absence of light, with a 
minimum lethal dose of 100-200 mg/kg upon systemic administration (1,4,10) in mice and 
rats. Thus, extensive preclinical studies have indicated PCI as a safe and a highly specific 
anticancer treatment; this usually depends on the photosensitizer and light properties used 
for illumination (1,4-10). 
 
As compared to most other anti-cancer cytotoxic drugs bleomycin has some unusual 
physico-chemical properties, including hydrophilicity and large size. This makes bleomycin 
an agent that to a large degree is taken up into cells by endoscytosis, with accumulation in 
endocytic vesicles severely limiting its activity (14). In accordance with this, preclinical 
studies have demonstrated that the anti-tumour activity of bleomycin was strongly 
enhanced using the PCI technology (15,16). 
 
Here we report on the “first-in-man” phase I clinical trial to examine the safety, tolerability 
and anti-tumour activity of photochemical internalization (PCI) of bleomycin with the 
photosensitizer TPCS2a (in the treatment of advanced/recurrent cutaneous and 
subcutaneous malignancies. 
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Materials and Methods 
 
This single-centre, dose-escalation phase I clinical trial was performed at University College 
Hospital (UCH), London, United Kingdom. The aims of the study were to assess the safety 
and tolerability of TPCS2a-mediated PCI with bleomycin and document the anti-tumour 
activity of the PCI treatment. This included determining the maximum tolerated dose (MTD), 
describing the dose-limiting toxicities (DLT), and evaluating body organs toxicity, skin 
photosensitivity and TPCS2a pharmacokinetics. 
 
This clinical trial was conducted in accordance with the Declaration of Helsinki and Good 
Clinical Practice Guidelines of the General Medical Council (UK). The trial protocol was 
approved by the South West Research Ethics Committee, National Health Service, UK (REC 
Reference Number 09/H0206/17). Every patient was discussed at the multidisciplinary team 
meeting at UCH and all patients were provided with a detailed information sheet and 
educated about the treatment and the commitment it required. Each patient signed an 
informed consent prior to joining the trial. A Dose Escalation Committee reviewed the safety 
findings of each cohort and agreed on the magnitude of the next dose level escalation. 
 
The patient population included adult patients with advanced and/or recurrent cutaneous 
or subcutaneous malignancies, with a performance status (PS) of 0-2 on the Eastern 
Cooperative Oncology Group (ECOG) scale and predicted life expectancy of at least 3 
months. For optimal monitoring, patients needed to be of I-IV Fitzpatrick skin type (Table 1). 
For inclusion in the study, recruited patients needed to be considered safe to receive 
bleomycin, should have discontinued radiotherapy for at least 2 weeks and chemotherapy 
for at least 6 half-life cycles prior to the administration of TPCS2a. Patients with tumours 
eroding into a major blood vessel were not recruited into this trial. 
 
A single target area or lesion was identified in each subject on Day -14 (Day 0 reflecting day 
of TPCS2a administration) and treatment progress of that area was documented. Patients 
with multiple malignant lesions or areas were assessed and treated.  Monitoring of vital 
signs, ECOG status and for adverse events took place at every scheduled hospital visit. 
Haematology and biochemistry blood profiling was also undertaken regularly and as per the 
trial’s protocol. Photosensitizer-related assessments were carried out at every visit and 
included: blood and urine testing for pharmacokinetic analysis, target lesion assessment 
(response) via clinical photography (aided by ultrasonography and histopathology) and skin 
photosensitivity testing and scoring (Table 2 and Figure 2). 
 
PCI treatment 
On Day 0, TPCS2a was administered by slow intravenous injection into the midcubital vein, 
with the patient constantly monitored during this process. Dexamethasone and 
chlorphenamine were administered soon after to reduce any potential allergic reaction 
effect. Ninety-six hours were allowed to elapse to allow the photosensitiser to distribute in 
the tumour and be taken up by the tumour cells. . The patient was kept in a dim-light side 
room to avoid photosensitivity reactions in the skin or the eyes, and monitored closely for 
adverse events. 
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On Day 4, bleomycin (fixed dose of 15,000 IU/m2) was administered by slow intravenous 
infusion under the supervision of an experienced oncologist.  Illumination of the target 
lesion or area took place three hours (±30 min) later using 652 nm diode laser light. Each 
illumination process covered a circle of up to 5cm in diameter and lasted 600secs at an 
irradiance of 100 mW/cm2, to achieve a fixed light dose of 60 J/cm2. A margin of 10mm 
beyond the macroscopic tumour margin was treated to eliminate any micro infiltration. 
Tissues subjected to the PCI treatment were infiltrated with 10-20ml of 0.5% Bupivacaine 
(with no vasoconstrictor) as an analgesic. The illumination process was performed with 
different regimens for pain management (awake, sedation, general anaesthesia) as specified 
under the results section. 
 
In the immediate post-treatment phase, the patient analgesic requirements were satisfied 
through special pain protocols. Dose escalating the patient’s own pain medication or 
prescribing patient-controlled analgesics was implemented when indicated. Medical and 
surgical unwanted events were dealt with immediately. Airway control was a priority (when 
managing patients with oral/oropharyngeal/laryngeal malignancies) as compromise can 
occur from the resulting local inflammatory reaction. Elective tracheostomy was 
implemented in the peri-treatment phase when indicated. Patients were instructed to take 
precautions to restrict exposure of their skin and eyes to light until otherwise instructed. 
Patients were discharged on Day 7 when clinically indicated, and were followed up on 
Day 14, Day 28 and at 3 months from the day of photosensitiser (Amphinex®) administration 
(Day 0). As part of this trial, each patient received one round of the PCI treatment only. Any 
other clinically indicated investigations or interventions were implemented without delay 
and according to the patient’s best interests.  
 
Dose escalation, dose-limiting toxicity and maximum tolerated dose 
The TPCS2a starting dose was 0.25 mg/kg and was to be escalated in successive dose groups 
of 3 patients according to a modification of Simon’s accelerated titration design (17). Doses 
were to be doubled until dose-limiting toxicity (DLT - a state where side effects are known to 
be severe preventing more treatment) was observed in one patient during 28 days’ follow-
up. Drug-related DLT was defined, recorded according to the Common Terminology Criteria 
for Adverse Events v3.0 (CTCAE), (Table 1). Since major reactions in the illuminated area 
would mainly be due to intended destruction of tumour tissue, a higher grade of toxicity 
was accepted inside this area. If a DLT was observed in one patient in a dose group, 
subsequent dose levels were to be escalated by 1.5 times until DLT occurred in at least two 
patients. If more than 33% of the patients at a given dose level report a DLT within the first 
28 days of treatment the maximum tolerated dose (MTD) would have been exceeded, and 
dose escalation would be stopped. MTD was then defined as the dose below. Based on the 
MTD a further six patients were to be treated at a dose level below the MTD as the principal 
investigator deemed to be sufficient for the treatment of lesions, (Figure 2).  
 
General and photosensitiser-related assessments  
I. Medical examination and investigations 
General medical examination was carried out at every patient’s visit. Routine blood testing 
was undertaken regularly to monitor body organs function.  
 
II. Unwanted and adverse events 
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Peri-treatment medical and surgical unwanted events were identified and dealt with 
promptly. Adverse events were recorded and reported according to ICH GCP guidelines. 
 
III. Pain scoring and patients’ performance status 
Pain was scored by the patient on a 10 cm visual analogue scale (VAS) on Day 4 (just after 
light application) and Day 5.  
 
IV. Blood and urine assessments for Pharmacokinetic (PK) analysis 
Blood and urine samples for pharmacokinetic analysis were taken on Days 0 (pre-TPCS2a, 
30 min and 4 hours post-TPCS2a administration), 2, 4, 7, 14, 28, and at the last visit (Table 2). 
Content of TPCS2a (Amphinex®) in plasma and urine was analysed by fluorescence 
spectroscopy.  
 
V. Skin photosensitivity testing and scoring 
- Skin photosensitivity was assessed and recorded at specified intervals throughout the trial 
(Days 0,1,3,6,14,28 and last visit). Skin photosensitivity tests were carried out with white 
light at two intensities: 500 lux (comparable to bright indoor light) and 100,000 lux 
(comparable to direct sunlight) for periods ranging of 30 seconds or 5 minutes (Table 2). 
Separate 0.8 cm2 spots on the inside of the arm were exposed to light and patients were 
evaluated at 1 and 24 hours after exposure.  
 
It was considered important to report any local skin changes, as these may reflect 
phototoxicity, including: erythema, oedema, blister formation, hypopigmentation, 
hyperpigmentation, scarring, atrophy, induration and skin defects. The scoring of skin 
photosensitivity was descriptive. 
 
VI. Target lesion assessment response 
Target lesion/area measurements by clinical examination (largest diameter), and 
ultrasonography [US] when applicable, were recorded at Days -14, 0, 28 and last visit. 
Clinical photography was carried out on Days 0, 7, 14, 28 and last visit (Table 2). Tissue 
specimens were sent for histopathological analysis, when appropriate, to assess response 
and tumour margins. Response was recorded according to “Response Evaluation Criteria in 
Solid Tumours” (RECIST version 1.1) under the categories Complete Response (CR), Partial 
Response (PR), Stable Disease (SD) or Progressive Disease (PD). Confirmed RECIST responses 
were those that have been confirmed at Day 28 (Table 1). 
 
Statistical evaluation 
Safety and response data were summarised using descriptive statistics by dose level. 
Statistical analysis comparing the response of the target lesion to the treatment with 
adverse effects due to photosensitivity was carried out using SPSS (version 20). 
 
 
 
 
 
 
 7  
 
Results 
 
In total 22 patients were enrolled in this trial, with the demographics outlined in Table 3. 
The majority of patients were Caucasians, with a mean age of 60 years and an ECOG of 0 
and 1 in 10 and 9 patients, respectively, while 3 patients had ECOG 2.  The majority of 
patients had squamous cell carcinoma of the head and neck but there were also a variety of 
other advanced and/or recurrent malignancies of the head and neck, torso and upper limbs 
including sarcoma, eccrine (adnexal) carcinoma and chemo-resistant ductal carcinoma 
(Fig.1). All patients had a predicted life expectancy of more than 3 months, and had 
previously received at least 1 surgical treatment for the same treated area along with 
chemo-radiation. Target lesions were identified, and parameters including tumour depth 
and longest diameter were recorded (Table 3). 
 
According to the dose escalation plan, patients were divided into the following cohorts: one 
starting dose (0.25mg/kg), three dose escalations (0.5, 1.0 and 1.5 mg/kg), one “selected 
optimal dose” with an increased number of patients (0.5mg/kg) and one dose de-escalation 
(0.125 mg/kg) (Figure 2). The “selected optimal dose” cohort was mainly based on the dose-
limiting toxicity (DLT) and maximum tolerated dose (MTD) information, which were actively 
examined during the trial as well as the therapeutic depth of effect. Sub-group analysis of 
the TPCS2a dose cohorts is illustrated in table 4.  
 
Twenty-one out of the twenty-two treated patients reached the 4-week follow-up where 
the DLT and MTD were assessed; all the safety data were also acquired. Only one patient 
died in the first 4 weeks following the treatment (Figure 1B). Twelve patients completed the 
clinical trial at the 3-month follow-up. Five out of the ten patients, who left the trial, 
required further treatment. Two patients suffered from local disease progression and 
required further intervention and further two suffered from complications of existing 
metastatic lung disease (Figure 2).  
 
Safety and tolerability of TPCS2a-mediated PCI with bleomycin 
The administration of TPCS2a was found to be safe and tolerable by all patients. There were 
no clinically meaningful changes in the vital signs when compared to baseline, furthermore 
there were no consistent patterns of change over time in mean haematology and 
biochemistry blood profiles. TPCS2a and the PCI treatment were not found to cause any 
negative direct effects on any of the monitored body organs. The ECOG performance status 
was generally unchanged after baseline in 15 patients; while it improved in 2 patients and 
worsened in 3 patients. Two patients did not have complete ECOG status data. 
 
There were no unwanted or adverse events in the first 96 hours until the administration of 
the chemotherapeutic agent and the initiation of the PCI treatment. Adverse events have 
been accurately recorded and classified into 3 categories: (1) PCI-treatment related, (2) 
Cancer-related, and (3) General medical/mental health-related. PCI-treatment related 
adverse events were either local or systemic (Table 5). The localised high pain level was the 
only unexpected event among the PCI-related adverse events.  Our clinical observation data 
suggested that pain was reported after few minutes from initiating the illumination 
procedure and escalated to maximal levels, then started to decline 1-2 hours later and 
returned to reasonable (clinically expected) levels at 5-7 hours. 
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Pain scoring on VAS was highest in the first cohort (0.25 mg/kg) immediately after light 
delivery (8.08 cm) as they were treated with loco-regional anaesthesia only. All subsequent 
patients received general anaesthesia or sedation (along with loco-regional anaesthesia), 
resulting in considerably better pain control reflected in lower VAS scores (Table 6). In the 
0.125 mg/kg cohort the VAS score unexpectedly was 7.67 immediately after treatment. In 
all groups the VAS score was substantially reduced 24 hours after light delivery with mean 
values ranging from 0.00- 2.38 cm for the different dose groups, with no obvious dose 
relationship. 
 
Cancer-related adverse events were all expected. Dysphagia was observed due to tumour 
growth, which was unrelated to the PCI treatment field. Two patients suffered from loco-
regional haemorrhage due to tumour invading the blood vessel walls, and the associated 
fistula formation. General medical and mental health-related adverse events were reported. 
The severity of adverse events was also recorded. It was found that the majority of PCI-
related adverse events (reported more than once) were seen in the cohort receiving 
photosensitiser (TPCS2a) at the dose of 1.5mg/kg (Tables 5 and 6). 
 
 
Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) 
No adverse events corresponding to the definition of dose limiting toxicity (DLT) were 
observed in the first two cohorts (0.25 and 0.5 mg/kg). One DLT was seen in the 1.0 mg/kg 
cohort and the next dose level was therefore 1.5 mg/kg. Two patients (out of the 3) in the 
1.5 mg/kg dose cohort experienced DLTs. One of these was a photosensitivity reaction 
(Grade 3 oedema and Grade 2 blisters to back of hands) 25 days after TPCS2a administration 
in a patient whose hands were exposed to strong sunlight for a prolonged period, against 
the protocol recommendations. The DLT in the other patient was a Grade 3 wound 
infection. These DLTs lead to the conclusion that the maximum tolerated dose (MTD) for 
TPCS2a-based PCI with Bleomycin had been exceeded, and the MTD was therefore agreed to 
be 1.0 mg/kg.  
 
Pharmacokinetics 
The mean plasma concentration of TPCS2a following TPCS2a administration in the four higher 
dose levels tested is presented in figure 3. In the 0.125 mg/kg dose level, some of the 
patients were retreated with PCI during the evaluation time, therefore this group could not 
be included in the pharmacokinetic analysis 
 
The highest mean TPCS2a concentration was observed at the sample point of 30 minutes 
(0.02 days) after TPCS2a administration. In the 0.25, 0.5 and 1.0 mg/kg dose levels, there was 
a near proportional relationship between dose and mean maximum concentration, while at 
the highest dose (1.5 mg/kg) the maximum concentration appeared to have plateaued. 
After a rapid first phase of elimination, levels of TPCS2a decrease monotonically towards 
zero through the whole assessment period of 90 days, with the exception of Day 7 in the 
1.5 mg/kg dose group, where the TPCS2a level was higher than on Day 4 (Table 7).  
 
The pharmacokinetic behaviour of TPCS2a was further analysed using a non-compartmental 
approach based on the last four measurements for each patient. There was no significant 
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difference between the dose levels neither in the mean elimination rates, nor in the mean 
elimination half-life (ranging from 15.4 to 21.7 days).  As expected, the mean values of 
AUC0– increased with increasing dose, ranging from 47 (µg/mL) x days in the 0.25 mg/kg 
group to 221 (µg/mL) x days in the 1.5 mg/kg group (Table 7). TPCS2a was still detectable in 
blood 90 days after administration in all evaluable dose levels. 
 
No TPCS2a was detectable in urine in the first 14 patients; therefore it was decided not to 
conduct urine analyses in the remaining patients.  
 
Photosensitivity testing and scoring 
There were no reported photosensitivity reactions in any patient to exposures of 500 lux 
(bright indoor light). At 100,000 lux (corresponding to direct sun light), photosensitivity was 
detected in at least one patient in all dose cohorts except the 0.125 mg/kg. All except one of 
the reactions were observed between Day 3 and the last visit. All reactions were mild, apart 
from one patient (1.5 mg/kg dose level) who had moderate (Grade 2) oedema and 
erythema. Most of the reactions resolved within 24 hours. There appeared to be a 
correlation between both the frequency and duration of observed photosensitivity reactions 
and TPCS2a dose.; this is based on qualitative assessment. This last aspect can be exemplified 
by the observation of skin photosensitivity at Day 90 in the 1.5mg/kg cohort and the 
absence of photosensitivity reactions beyond Day 14 in the 0.25mg/kg cohort (Figure 4). 
  
Tumour Response 
The most striking finding from this trial is the strong tumour responses. The starting dose of 
TPCS2a was set at a level not expected to trigger a PCI response, however there appeared to 
be a localized synergistic effect with the photo-activation.  
 
RECIST evaluations were available for target lesions of 16 patients at Day 28 and for 11 
patients at their last visit, a minimum of four weeks later. At Day 28, complete response (CR) 
was achieved in 11 patients (68.8%), partial response (PR) in 2 (12.5%), stable disease (SD) in 
2 (12.5%) and progressive disease (PD) in only one patient. Furthermore, the outcome at the 
last clinic review was complete response (CR) in 5 (45.4%) patients, partial response (PR) in 
2 (18.2%), stable disease (SD) in 2 (18.2%) and progressive disease (PD) 2 (18.2%) patients 
(Table 8). This effect was not only confined to squamous cell carcinomas (Figures 5 and 6) 
but was also observed in other tumour types such as sarcoma (Figure 7) and chemo-
resistant ductal carcinoma (Figures 8 and 9) which have traditionally been very resistant to 
most treatment modalities. 
 
At 28 days, target lesions had completely resolved in all 4 patients in the 0.25 mg/kg cohort. 
In the 0.5 mg/kg cohort, 4/7 patients had a CR. As the original dose escalation had 
demonstrated good efficacy even in the lowest dose level of 0.25 mg/kg (100% CR), it was 
decided to evaluate the clinical response at a lower dose level of 0.125 mg/kg (dose se-
escalation). However, the clinical response in this dose group was inferior to that observed 
in the higher dose groups and this dose de-escalation group was not included in our RECIST 
evaluations (Table 8).  
 
Five patients succumbed to their illness, caused by complications of the disease at distant 
organs. Two with pre-existing lung metastasis died of pulmonary haemorrhage, one poorly 
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controlled asthma with long standing history of opiate consumption succumbed to multi-
organ failure and 2 patients suffered a cardio-respiratory arrest. No PCI-related deaths were 
recorded. 
 
Target lesion, local tumour-specificity and optimal photosensitiser dose 
Identifying a target lesion for every patient included in this trial represented a challenge 
(Figures 1A, 1B, 1F and 1G). Our data has clearly proven the ability of PCI in eliminating a 
variety of malignancies, with preservation of adjacent non-malignant tissues (Figures 5- 10). 
 
In patients with cutaneous malignancies, it was observed that after illumination, the 
malignant area turned necrotic, while the surrounding normal skin, although illuminated, 
remained intact (Figures 5 Month 3, 6 Day 45, 7 Day 28). Likewise, when a subcutaneous 
malignancy was illuminated, the cancerous lesion became necrotic (Figures 8 and 10) with 
no damage to the illuminated healthy overlying skin (Figure 10). 
 
Based on the “target lesion” data, the 0.25mg/kg cohort achieved a complete tumour 
response to therapy (as per RECIST). However, the overall treatment data (including target 
lesions and all other treated lesions) have shown that the 0.5mg/kg cohort achieved a 
higher tumour therapeutic depth. As such, a decision was made to highlight the 0.5mg/kg as 
the “selected optimal dose” cohort. 
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Discussion 
 
The new photosensitiser TPCS2a when used in combination with bleomycin was 
demonstrated to be safe and tolerable by all patients, and was an acceptable treatment 
option in a very complex population of patients with various cutaneous and/or sub-
cutaneous malignancies (at day 28, CR was achieved in 11/16 patients). No PCI-related 
death was identified in any of the 5 patients who succumbed to their illness during the 
operation of this trial.  
 
The unexpected high levels of pain experienced during illumination were eliminated by the 
use of general anaesthesia or intravenous sedation. Post-intervention pain was managed 
through special pain management protocols, and our data have shown significant reduction 
in pain levels 24 hours post illumination. This discomfort was localized to the site of the 
malignancy. Based on clinical observations, the pain appeared to be correlated with surface 
area of tumour exposed to illumination. We hypothesize that the induction of acute necrosis 
with the release of intracellular degradation products may have stimulated small pain fibres 
either directly or through histamine, chemokines and cytokines release (18). 
 
One of the DLTs of TPCS2a-mediated PCI was skin photosensitivity. The most severe event 
seen was at the dose of 1.5 mg/kg in a patient who did not follow the general precautions 
given to prevent skin sensitivity reactions. Controlled skin photosensitivity measurements 
indicated that skin photosensitivity was dose dependent, being substantially less at the 
0.25 mg/kg dose, which still provided an effective therapeutic response.  
 
Skin photosensitivity was observed for a substantial period of time following TPCS2a 
administration, particularly at higher doses but was clinically manageable. This prolonged 
effect was also reflected in the pharmacokinetic measurements, which demonstrated that 
TPCS2a has a slow elimination rate (half-life 15-22 days) and was still detectable in blood 90 
days after administration in all evaluable dose levels. There was no indication that the 
employment of PCI increases the reported skin toxicities of bleomycin (19), also in 
accordance with animal studies indicating that the administration of bleomycin did not 
increase skin photosensitivity over what was seen with TPCS2a and illumination alone 
(14,16). 
 
A very interesting finding from this trial was the strong tumour responses observed. 
Although the MTD of TPCS2a was determined to be 1.0 mg/kg, strong anti-tumour effects 
were observed at all doses from the starting dose of 0.25 mg/kg. Apart from the inferior 
response observed when the dose was reduced to half the starting dose (de-escalation 
cohort), there was no obvious correlation between the TPCS2a dose and the tumour 
response, with seemingly similar effects observed at 0.25 and 1.5 mg/kg. Also good tumour 
responses were observed across several different tumour types, such as squamous cell 
carcinomas, sarcoma and chemo-resistant ductal carcinoma, which have traditionally been 
very resistant to most treatment modalities. The preliminary tumour response results from 
the present study indicate that a photochemical dose sufficient to produce a complete 
tumour response can be employed without inducing severe damage to surrounding normal 
tissue within the illuminated field.  
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The PCI treatment would appear to induce an immediate but gradual process, with the 
tumour tissue slowly developing necrosis over a number of weeks. PCI has shown good 
potential of high tumour selectivity when treating cutaneous and sub-cutaneous 
malignancies. In contrast and based on clinical observation data, local treatment of similar 
lesions with photodynamic therapy using the Foscan® photosensitizer induces a process 
after few days but more rapid tumour necrosis with considerably less tumour specificity. 
 
This suggestion of tumour selectivity was somewhat unexpected, since in mouse xenograft 
studies the distribution of TPCS2a has not been demonstrated to discriminate well between 
tumour tissue and adjacent normal skin (16). However, in a hamster cheek pouch model for 
head and neck cancer, some tumour selectivity of TPCS2a accumulation has been observed 
(16), and significant selectivity (5-7 times) between tumour tissue and underlying muscle 
tissue has been observed in mice (20), indicating that some specificity may be due to 
selective accumulation of TPCS2a in the tumour tissue. 
 
Bleomycin in itself, is not very tumour-selective, however it is more toxic to highly 
proliferating cells and it is possible that the cellular uptake (21), or the biological effect of 
bleomycin may be higher in cancer cells than in surrounding normal cells in the skin, 
although, at least to our knowledge, this has not been formally investigated. The acute dose 
limiting side effects of bleomycin, including myelosuppression, would not be expected to be 
increased by a locally directed therapy such as PCI, and this was confirmed to be the case, 
and cumulative pulmonary toxicity seen with bleomycin (22) is mitigated by PCI treatment 
being only a single administration. 
 
As well as the tumour response data described, the survival data were encouraging. The 
mean survival time of all patients studied (excluding the 0.125mg/kg cohort) was 17 
months, and several patients with locally recurrent malignancies (without distant 
metastases) had remarkably long survival, with two patients still being alive more than 4 
years after treatment, and additional 4 patients living more than 2 years after treatment. 
Only two of the long survivors received subsequent chemotherapy and given the mean age 
and comorbidities in these patients. 
 
PCI targeting disease at molecular level 
The Photochemical internalisation (PCI) technology has been developed in various in vitro 
systems and very promising effects have been observed in many animal models. In 
preclinical studies, it has been found that PCI can enhance the effect of endocytosed 
molecules even when the target cells are exposed to subtoxic illumination doses (12-14).  
This predicts that PCI may be able to produce deeper effects than achievable by pure 
photodynamic therapy (13,23). However, it was rather surprising that in this study complete 
tumour responses were observed in tumours with a depth of up to 35 mm. The fluence 
reaching the deepest part of such tumours is exceedingly small, implying that either the 
light dose needed to induce release of sufficient amounts of Bleomycin is smaller than 
anticipated, or that mechanisms other than the cytotoxic effect of Bleomycin may be 
contributing in the deeper layers of the tumour. One possible mechanism is the induction of 
an immunological response, which has been described for photochemical treatments, and 
which could also explain the selectivity of the treatment (24).  
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In addition to the possible immune-stimulating induction of necrosis, inflammation and 
cytokine production (25), it has recently been reported that PCI can enhance antigen 
presentation on major histocompatibility complex class I, an important element in the 
generation of an effective immune response to tumours (26,27). There were no obvious 
ischaemic effects observed in surrounding normal tissues, which may imply that if blood 
supply is affected by the treatment it is limited to more fragile tumour neovascularisation. 
 
An interesting aspect of the PCI technology is that TPCS2a and similar molecules, in contrast 
to many other photosensitisers, are not affected by many of the more common drug 
resistance mechanisms (28,29). For example, the effect of TPCS2a is not affected by the 
expression of the ABCG2 transporter, which contributes to drug resistance in highly drug-
resistant putative cancer stem cells (30). Thus, PCI has a very interesting potential for 
treating tumours with acquired drug resistance (31) and perhaps even the inherently 
chemo-resistant cancer stem cells.  
 
The PCI technology also has potential beyond use with cytotoxic drugs, such as with 
macromolecular agents. Many macromolecules are totally dependent on endosomal release 
to reach intracellular targets and therefore have the potential to have greatly enhanced 
activity when combined with PCI. For example, in vitro studies have shown that PCI can 
enhance the effect of a protein toxin more than 1000-fold (31). This raises the possibility 
that PCI may be able to cause ‘release’ of the toxins for a cytotoxic effect in the illuminated 
target area at doses where there is no effects in other (non-illuminated) parts of the body. A 
particularly interesting option is to combine PCI with antibody-based molecules, such as 
immunotoxins or antibody drug conjugates with intracellular targets. Thus, in vitro studies 
have shown that PCI can enhance the effect of immunotoxins directed to several different 
relevant cancer surface markers such as the EGFR (30, 32) and others (33,34), and in vivo 
data has also shown very potent and specific effects of PCI with a recombinant immunotoxin 
directed to a cell surface marker that is overexpressed on melanoma and several other 
cancer types (11).  
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Conclusion 
The very promising results of the TPCS2a-mediated photochemical internalisation (of 
chemotherapeutic agent bleomycin) in this heavily pretreated population suggest it may 
have an important role in interventional oncology.  
 
It was very encouraging to observe the uniform effect of PCI in causing tumour death on a 
number of very aggressive cutaneous and sub-cutaneous malignancies including squamous 
cell carcinoma, sarcoma, eccrine (adnexal) carcinoma and chemo-resistant ductal 
carcinoma. The study paves the way for further clinical development of the PCI/ 
TPCS2a/Bleomycin combination, as well as clinical testing of the technology with other types 
of drug molecules on different tumour types. 
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Tables 
 
Table 1: The parameters and their sub-classifications employed for patient’s inclusion criteria, 
evaluation and assessment of outcome. 
 
Fitzpatrick skin type  
Type I Pale white Type IV Moderate brown 
Type II White Type V Dark brown 
Type III Cream white Type VI Deeply pigmented dark brown to black 
  
ECOG  
0 Fully active 3 Capable of only limited self-care 
1 Restricted in physically strenuous activity 4 Completely disabled 
2 Ambulatory and capable of all self-care 5 Dead 
  
CTCAE  
(i) Photosensitivity Grade 2 outside the illuminated area, except for areas exposed for skin sensitivity tests and 
areas wilfully exposed for re-introduction to normal light. 
(ii) Photosensitivity Grade 4 inside the illuminated area. 
(iii) Neutropenia or thrombocytopenia Grade 4. 
(iv) All other toxicity reactions (excluding nausea and vomiting) of ≥ Grade 3. 
  
RECIST criteria  
Complete response (CR): Disappearance of all target lesions. 
Partial response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking 
as reference the baseline sum LD. Confirmed at 4 weeks.  
Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking 
as references the smallest sum LD.  
Progressive disease (PD): At least a 20% increase in the sum of LD of target lesions taking as references the 
smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.  
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Table 2:  The peri-PCI treatment visits highlighting the required assessments and 
procedures. 
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Bloods test             
Pharmacokinetics             
Lesion measurement             
Clinical Photography             
TPCS2a             
Bleomycin given             
Laser treatment             
Pain assessment             
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Skin photo score             
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Table 3: Patients demographics, target lesions and Amphinex dosing parameters. 
 
 Patients  Patients 
 No. = 22  No. = 22 
Gender  Target lesion (TL) location  
Male 11 Head and neck 17 
Female 11 Torso – front 3 
  Torso – back  1 
Age (at time of treatment)  Arm 1 
Mean±SD 60.4±13.3   
Minimum-Maximum 34-82 TL – longest diameter (mm)  
  Mean ±SD 38 ±21.5 
Race  Minimum-Maximum 15-120 
Caucasian 20   
Asian 2 TL – depth (mm)  
  Mean ±SD 16.0 ±9.5 
Fitzpatrick skin type  Minimum-Maximum 2-38 
Type I 4   
Type II 7 Trial cohorts  
Type III 8 Starting dose 1 
Type IV 3 Dose escalation 3 
  Dose de-escalation 1 
ECOG  Optimal photosensiter 1 
0 10   
1  9 Trial cohorts – dosing mg/kg  
2 3 0.125 3 
  0.25 (starting dose) 4 
Diagnosis  0.5 (selected photosensitizer) 9 
Squamous cell carcinoma 16 1.0 3 
Sarcoma 1 1.5 3 
Ductal carcinoma 4   
Eccrine (Adnexal) carcinoma 1   
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Table 4: Patients demographics and target lesion parameters as per TPCS2a dosing groups. 
 
 0.125 mg/kg 0.25 mg/kg 0.5 mg/kg 1.0 mg/kg 1.5 mg/kg 
Patients No. 3 4 9 3 3 
      
Gender      
Male 2 (67%) 4 (100% 2 (22%) 2 (67%) 1 (33%) 
Female 1 (33%) 0 (0%) 7 (78%) 1 (33%) 2 (67%) 
      
Age (at time of treatment)      
Mean ±SD 58.0 ±7.0 69.8 ±12.1 56.4 ±12.8 49.7 ±19.1 72.0 ±7.8 
Minimum-Maximum 52-65 56-82 40-73 34-72 67-81 
      
Race      
Caucasian 3 (100%) 4 (100%) 8 (89%) 2 (67%) 3 (100%) 
Asian 0 (0%) 0 (0%) 1 (11%) 1 (33%) 0 (0%) 
      
Fitzpatrick skin type      
Type I 0 (0%) 2 (50%) 2 (22%) 0 (0%) 0 (0%) 
Type II 0 (0%) 0 (0%) 4 (45%) 1 (33%) 2 (67%) 
Type III 3 (100%) 2 (50%) 2 (22%) 0 (0%) 1 (33%) 
Type IV 0 (0%) 0 (0%) 1 (11%) 2 (67%) 0 (0%) 
      
ECOG      
0 1 (33%) 2 (50%) 6 (67%) 0 (0%) 1 (33%) 
1  2 (67%) 1 (25%) 3 (33%) 2 (67%) 1 (33%) 
2 0 (0%) 1 (25%) 0 (0%) 1 (33%) 1 (33%) 
      
Diagnosis      
Squamous cell carcinoma 3 (100%) 3 (75%) 7 (77.8%) 2 (67%) 1 (33%) 
Sarcoma 0 (0%) 1 (25%) 0 (0%) 0 (0%) 0 (0%) 
Ductal carcinoma 0 (0%) 0 (0%) 2 (22.2%) 1 (33%) 1 (33%) 
Eccrine (Adnexal) carcinoma 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (33%) 
      
Target lesion (TL) location      
Head and neck 3 (100%) 4 (100%) 6 (66.7%) 2 (67%) 2 (67%) 
Torso – front 0 (0%) 0 (0%) 2 (22.2%) 0 (0%) 1 (33%) 
Torso – back  0 (0%) 0 (0%) 1 (11.1%) 0 (0%) 0 (0%) 
Arm 0 (0%) 0 (0%) 0 (0%) 1 (33%) 0 (0%) 
      
TL – longest diameter (mm)      
Mean ±SD 30.3±17.0 48.8 ±47.7 34.6 ±11.4 48.3 ±2.9 31.3 ±2.3 
Minimum-Maximum  20-50 20-120 15-55 45-50 30-34 
      
TL – depth (mm)      
Mean ±SD 16.3 ±11.8 17.5 ±9.5 14.3 ±8.2 23.3 ±15.6 11.0 ±3.6 
Minimum-Maximum 9-30 4-25 2-25 7-38 8-15 
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Table 5: The adverse events (observed more than once per patient) and as per severity. The 
adverse events have been classified into PCI-related (directly linked to PCI treatment), 
cancer-related (directly linked to the natural progression of the malignancy) and general 
medical/mental health related (directly linked to the patient’s general medical and mental 
health). Each event was highlighted according to the clinical judgment of the treating team as 
either being an “expected” event or “unexpected” event. 
 
Adverse event Expected event or not Incidence (No. = 22) 
   
Mild adverse events: transient and easily tolerated. 15 patients 
Moderate adverse events: causes the patient discomfort and 
interrupts the patient’s usual activities. 
10 patients 
Severe adverse events: causes considerable interference with 
the patient’s usual activities, and may be incapacitating or life-
threatening. 
14 patients 
   
PCI-related (observed more than once) 
Localised pain Unexpected 9 patients 
Localised erythema Expected 3 patients 
Localised swelling Expected 3 patients 
Localised infection Expected 2 patients 
Localised sensory disturbance Expected 4 patients 
Nausea and vomiting Expected 6 patients 
Photosensitivity skin reaction - simple Expected 3 patients 
Photosensitivity skin reaction - pruritus Expected 3 patients 
   
Cancer-related (observed more than once) 
Dysphagia  Expected 2 patients 
Local haemorrhage Expected 2 patients 
Fistula formation Expected 2 patients 
Death Expected 5 patients 
   
General medical/mental health-related (observed more than once) 
Dyspepsia Expected 2 patients 
Drowsiness Expected 2 patients 
Constipation Expected 3 patients 
Fatigue Expected 2 patients 
Respiratory failure Expected 2 patients 
Panic attack Expected 2 patients 
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Table 6: The incidence and severity of adverse events are shown for the different TPCS2a 
dosing groups.  
 
 
 0.125 mg/kg 0.25 mg/kg 0.5 mg/kg 1.0 mg/kg 1.5 mg/kg 
Number of patients 3 4 9 3 3 
Total adverse events1 9 6 47 7 35  
PCI-related adverse events1 4 5 10 1 24 
      
Total PCI-related adverse events1 (observed once or more) 
Mild 4 (100%) 2 (40%) 4 (40%) 1 (100%) 19 (79%) 
Moderate 0 (0%) 0 (0%) 2 (20%) 0 (0%) 3 (13%) 
Severe 0 (0%) 3 (60%) 4 (40%) 0 (0%) 2 (8%) 
      
PCI-related pain scoring (in cm on VAS) 
Immediately after illumination 7.67 8.08 4.28 1.70 5.05 
24 hours after illumination 2.47 1.45 2.62 0.00 1.72 
      
PCI-related adverse events2 (observed more than once) 
Mild 2 (100%) 2 (40%) 4 (40%) 1 (100%) 11 (68.8) 
Moderate 0 (0%) 0 (0%) 2 (20%) 0 (0%) 3 (18.7) 
Severe 0 (0%) 3 (60%) 4 (40%) 0 (0%) 2 (12.5) 
      
Cancer-related adverse events2 (observed more than once) 
Mild 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Moderate 0 (0%) 0 (0%) 4 (50%) 2 (67%) 0 (0%) 
Severe 0 (0%) 0 (0%) 4 (50%) 1 (33%) 0 (0%) 
      
General medical/mental health-related adverse events2 (observed more than once) 
Mild 1 (33%) 0 (0%) 3 (50%) 0 (0%) 0 (0%) 
Moderate 2 (67%) 1 (100%) 2 (33%) 1 (50%) 1 (100%) 
Severe 0 (0%) 0 (0%) 1 (17%) 1 (50%) 0 (0%) 
      
1Total adverse events considered possibly or probably related (observed once or more). Patients could have AEs 
of more than one severity or intensity. 
2Total adverse events considered possibly or probably related (observed more than once). Patients could have 
AEs of more than one severity or intensity. 
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Table 7: The concentration of TPCS2a in patient plasma samples was measured by 
fluorescence spectroscopy.  
 0.25 mg/kg 0.5 mg/kg 1.0 mg/kg 1.5 mg/kg 
Number of patients 4 9 3 3 
     
Maximum concentration of TPCS2a in plasma (μg/mL) 
Mean ±SD 5.7 ±1.2 10.3 ±1.3 16.9 ±3.0 18.2 ±2.6 
Minimum-Maximum  4.2–6.8 8.6–12.1 13.5–19.4 15.5–20.6 
     
Daily elimination rate of TPCS2a in plasma 
Mean ±SD 0.036 ±0.004 0.040 ±0.074 0.046 ±0.074 0.033 ±0.006 
Minimum-Maximum  0.033–0.041 0.031–0.055 0.038–0.052 0.027–0.038 
     
Elimination half–lives of TPCS2a in plasma (days) 
Mean ±SD 19.6 ±1.9 18.0 ±3.0 15.4 ±2.6 21.7 ±3.7 
Minimum-Maximum  16.8–21.1 12.7–22.6 13.2–18.3 18.0-25.5 
     
AUC0– of TPCS2a in plasma (μg/mLxdays) 
Mean ±SD 47 ±10 76 ±18 114 ±32 221 ±50 
Minimum-Maximum  40–60 49–100 81–146 183–277 
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Table 8: Investigator evaluation of response of the target lesion. The evaluation of the 
response of the target lesion to the treatment is shown for the safety and the per protocol 
populations. The responses were evaluated according to the RECIST criteria.  
 
 0.25 mg/kg 0.5 mg/kg 1.0 mg/kg 1.5 mg/kg 
Total number of patients 
included 
4 9 3 3 
Number of patients (Day 28) 4 7 2 3 
Number of patients (Last review) 2 6 1 2 
     
Day 28 (19 patients)     
Complete response 4 (100%) 4 (44%) 2 (67%) 1 (33%) 
Partial response 0 (0%) 0 (0%) 0 (0%) 2 (67%) 
Stable disease 0 (0%) 2 (22%) 0 (0%) 0 (0%) 
Progressive disease 0 (0%) 1 (11%) 0 (0%) 0 (0%) 
Missing 0 (0%) 2 (22%) 1  (33%) 0 (0%) 
     
Last visit (11 patients)     
Complete response 2 (100%) 2 (33%) 0 (0%) 1 (50%) 
Partial response 0 (0%) 1 (17%) 0 (0%) 1 (50%) 
Stable disease 0 (0%) 2 (33%) 0 (0%) 0 (0%) 
Progressive disease 0 (0%) 1 (17%) 1 (100%) 0 (0%) 
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Figures 
 
Figure 1: Sample of the palliative patients treated under the phase I PCI trial protocol. All disease 
progression described occurred prior to the PCI treatment. (A) 56-year-old male with chondroblastic 
osteosarcoma in the right mandible. He failed 3 surgical resections with reconstruction and chemo-
radiation. (B) 45-year-old male with squamous cell carcinoma of the neck. He failed 3 surgical 
resections with reconstruction and chemo-radiation. The primary cancer also metastasised to the 
lungs and liver. This is the only patient who succumbed to his illness in his first 4 week on the trial. 
(C) 61-year-old female with metastatic squamous cell carcinoma (SCC) to the torso (back). The 
primary malignancy was a tongue base SCC with metastasis to the cervical and axillary lymph nodes. 
Had multiple failed interventions to the primary site. (D) 46-year-old female with metastatic ductal 
carcinoma to the torso (anterior). The primary breast cancer also metastasised to the brain, spine, 
lungs and liver. (E) 72-year-old female with metastatic (chemo-resistant) ductal carcinoma to the 
arm. The primary breast cancer also metastasised to the axillary and cervical lymph nodes. (F) 35-
year-old male with squamous cell carcinoma of the floor of mouth and neck. This patient failed 
surgery, chemo-radiation and photodynamic therapy. The cancer metastasised to the right lung and 
required pneumonectomy. (G) 73-year-old male with oral squamous cell carcinoma. This patient 
failed multiple surgical interventions with reconstruction, as well as chemo-radiation. 
 
Figure 2: Top diagram: Flow chart of the trial progress: initial recruitment, follow-up at Day 28, 
follow up after Day 28 and last review (Days 78-122). Bottom diagram: the process of dose 
escalation, de-escalation and fixation at the potential optimal dose, also included are the number of 
patients per cohort. 
 
Figure 3: The new photosensitiser TPCS2a (Amphinex) pharmacokinetics in blood. The concentration 
of TPCS2a in plasma samples from patients in the dose cohorts 0.25 – 1.5 mg/kg was analysed by 
fluorescence spectroscopy.  
 
Figure 4: Photosensitivity test results. The percentage of patients who experienced a response to the 
photosensitivity test (the most severe response observed at any time point) is shown for the dose 
groups 0.25-1.5 mg/kg (at 0.125 mg there were no responses). The erythema responses to 5 min 
100 000 lux illumination are shown. Oedema was only observed in two patients in the 1.5 mg/kg 
dose cohort (1 mild and 1 moderate). Also the device to deliver the light for photosensitivity testing 
is shown. 
 
Figure 5: 61-year-old female with metastatic squamous cell carcinoma (SCC) to the torso (back). The 
primary malignancy was a tongue base SCC with metastasis to the cervical and axillary lymph nodes. 
The patient had multiple failed interventions to the primary site. The left hand column images shows 
the shielding around the lesion after including 10mm of macroscopically healthy looking tissue 
within the treatment field to eliminate any chance of micro-infiltration. Surface illumination with 
652nm diode laser was applied to activate the PCI process (TPCS2a dose 0.5mg/kg). The right hand 
column images showing the cancerous lesions on Day -14 and Day 28 where complete tumour death 
(confirmed by histopathology) can be seen without any serious effect on the non-malignant 
surrounding tissue. Month 3 image shows on-going healing process. Surgical biopsies have been 
acquired from the centre of ulceration and were found tumour-free.  
 
Figure 6: This 83-year-old Caucasian male was diagnosed with squamous cell cancer of the right face 
and scalp. The rapidly growing aggressive tumour overcame all previous interventions including a 
major ablative resection with reconstruction, followed by chemoradiation. The 2 cancerous islands 
of the right face have extended to involve the whole right face in a short period of time (Day -28 to 
Day -7). The “target lesion” represented an extensively eroding tumour mass of the right face (Day 
 26  
 
0), (TPCS2a dose 0.25mg/kg). Post illumination Day 4 was associated with immediate changes in 
tissue colour (redness) with transudate/exudates (yellow in colour) leakage from the face; also this 
was associated with periorbital swelling. Day 7 was associated with further clinical changes 
(blanching of tissue) which could be attributed to the bleomycin release. The subsequent days 
following (Days 14-28) were associated with marked tissue changes and tumour shrinkage (necrosis). 
The complete response of the treated area could be clearly seen following the surgical removal of 
the dead tissue on Day 40. All the illuminated areas have also responded favourably to the 
treatment, including the right temporo-parietal-occipital region. Further tumour areas not treated 
by our limited non-interstitial protocol included tumour deeper to right temporal region and right 
supraorbital area.  
 
Figure 7: This 56-year-old Caucasian male was diagnosed with chondroblastic osteosarcoma in the 
right mandible. Initially the patient underwent surgical resection with free tissue transfer 
reconstruction, followed by chemoradiation. The rapidly growing aggressive tumour overcame all 
previous interventions and most recently two major ablative resections with reconstruction. The 
remaining bulk of the later flap can be seen at the bottom of each image. The tumour has eroded 
through the cheek resulting in a large fistula (Day -10) and continues to grow at high and unusual 
rate. The “target lesion” was an exophytic tumour mass at the junction of the right oral commissure 
and the remaining pectoralis major flap inferiorly; 0.25mg/kg TPCS2a was administered on Day 0. 
Surface illumination based photochemical internalization (PCI) was implemented on Day 4 and all 
tumour area was subjected to surface illumination; this phase was associated with immediate 
changes in tissue colour (blanching). Further clinical changes (indicative of tissue necrosis) could be 
seen on Days 7, 10 and 14. On Day 14 a fraction of the titanium plate became visible. The “target 
lesion” changed colour similarly to the adjacently treated tissues and disintegrated and could not be 
seen on Day 21. All the illuminated areas have also responded favourably to the treatment.  This 
includes tumour anterior to the tragus, superior aspect of the remaining pectoralis major flap and 
the tumours masses growing above the titanium plate (Days 21 and 28). Further tumour areas not 
treated by our limited non-interstitial protocol included tumour deeper to the illuminated area, 
posterolateral tongue, tongue base and recurred tumour inside the bulk of the pectoralis major flap. 
The patient left the trial on day 45 to receive further life-saving interventions.  
 
Figure 8: (A) Ultrasonography images of a 48-year-old female with heterogeneous subcutaneous 
ductal carcinoma at the level of the left sternal border (Day -14) with Doppler signal demonstrated 
within it, and no cortical irregularity or erosion to the underlying hard tissue structures were 
detected. The Day 28 image revealed no recordable Doppler flow in the heterougeneous soft tissue 
and normal appearance to the underlying bony structures. Biopsies acquired from the soft tissue and 
bone was tumour free. (TPCS2a dose 0.5mg/kg); (B) Ultrasonography images of a 67-year-old male 
diagnosed with right glosso-tonsillar fold squamous cell carcinoma (Day -14). The carcinoma was 
non-existent on Day 28 and biopsies confirmed tumour-free region. (TPCS2a dose 0.25mg/kg). 
 
Figure 9: (A) Histopathology images acquired from a78-year-old male with squamous cell carcinoma 
of the face on Day 28. Both sections of the tumour margin and the necrotic mass revealed no viable 
tumour cell. (TPCS2a dose 0.25mg/kg); (B) Histopathology image of an US-guided core biopsy (Day 
28) of a 67-year-old male diagnosed with right glosso-tonsillar fold squamous cell carcinoma. The 
biopsy showed no viable tumour cells. (TPCS2a dose 0.25mg/kg). 
 
Figure 10: Clinical images of a 48-year-old female with subcutaneous ductal carcinoma at the level of 
the left sternal border. The skin overlying the carcinoma was tumour-free and light illumination was 
delivered through the skin to the underlying cancerous tissue. Comparing images of Day -14 to Day 
28 revealed no damage to the skin confirming the high specificity of the PCI treatment. The US 
images are shown in Figure 8A.  
